| Literature DB >> 23125894 |
Martin A Baraibar1, Liang Liu, Emad K Ahmed, Bertrand Friguet.
Abstract
Protein damage mediated by oxidation, protein adducts formation with advanced glycated end products and with products of lipid peroxidation, has been implicated during aging and age-related diseases, such as neurodegenerative diseases. Increased protein modification has also been described upon replicative senescence of human fibroblasts, a valid model for studying aging in vitro. However, the mechanisms by which these modified proteins could impact on the development of the senescent phenotype and the pathogenesis of age-related diseases remain elusive. In this study, we performed in silico approaches to evidence molecular actors and cellular pathways affected by these damaged proteins. A database of proteins modified by carbonylation, glycation, and lipid peroxidation products during aging and age-related diseases was built and compared to those proteins identified during cellular replicative senescence in vitro. Common cellular pathways evidenced by enzymes involved in intermediate metabolism were found to be targeted by these modifications, although different tissues have been examined. These results underscore the potential effect of protein modification in the impairment of cellular metabolism during aging and age-related diseases.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23125894 PMCID: PMC3483731 DOI: 10.1155/2012/919832
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Cellular pathways and network analysis of proteins reported to be increasingly modified in senescent WI-38 human fibroblasts. (a) Primary subcellular location of modified proteins previously reported in senescent fibroblasts. Rare primary localization terms were grouped as Other representing less than 6% of total identifications. (b) Proteins were grouped by canonical pathways through the use of Ingenuity Pathways Analysis (Ingenuity Systems, http://www.ingenuity.com/). The bars represent the canonical pathways identified, named in the x-axis. The y-axis shows the −log of the P value calculated based on Fisher's exact test. The dotted line represents the threshold above which there are statistically significantly more genes in a biological function than expected by chance. (c) Protein networks were obtained using Ingenuity Pathway. Proteins in red correspond to some of the proteins identified as increasingly modified in senescent fibroblasts. White open nodes indicate proteins not identified in this analysis, but associated with the regulation of some of the proteins identified. Information about the analysis of biological functions and pathways as well as network interactions is available at the Ingenuity Pathway Analysis website. A line denotes binding of proteins, whereas a line with an arrow denotes “acts on.” A dotted line denotes an indirect interaction.
Figure 2Cellular localization and functional grouping of modified proteins identified during aging and age-related diseases. (a) Primary subcellular location of the identified modified proteins. (b) Functional grouping of modified proteins through the use of Ingenuity Pathways Analysis. The bars represent the biological functions identified, named in the x-axis. The dotted line represents the threshold above which there are statistically significantly more genes in a biological function than expected by chance.
Functional categories of proteins identified as increasingly modified in aging and age-related diseases. Fisher exact test was used and the P value refers to the probability that each biological function assigned is due to chance alone.
| Function |
| Modified proteins |
|---|---|---|
| Inflammatory response | 3.7 | ACO2, ACTB, ALDH2, ALDOA, ARG1, ENO1, GAPDH, HSPA5, P4HB, PDIA3, PRDX1, PRDX6, SELENBP1, TKT, TPI1 |
| Carbohydrate metabolism | 6.0 | ALDOA, ENO1, ENO2, FBP1, GAPDH, PGAM1, PGK1, PKLR, PKM2, TPI1, ACADM |
| Nucleic acid metabolism | 1.4 | ACOT8, ALDH2, ATP5A1, ATP5B, CKM, DPYSL2, GNB1, SCP2, SUCLA2, MDH2 |
| Cell death | 1.0 | ACAT1, ANXA2, ARG1, ATP5A1, G6PD, G5TM5, HSPD1, SLC1A2, PIN1, PRDX2, PARK7, TUBA1A |
| Lipid metabolism | 6.9 | MDH1, MDH2, SDHA, SDHB, OGDH, SUCLA2, ACOT8, FABP4, GSTP1, SCP2 |
| Free radical scavenging | 1.1 | ALB, SOD1, SOD2, PRDX1, PRDX2, PRDX6, VDAC1, ALDH2, GPX1 |
| Protein folding | 6.9 | HSP90AA1, HSPA1A, ERP29, HSPD1, HSPA8, HSP90AB1 |
| Amino acid metabolism | 5.4 | ARG1, DDAH1, IVD, OAT, PAH, CKM, PLOD3 |
| Protein synthesis | 5.8 | EEF2, GNB2L1, RPS6KB1, TUFM, WARS, CCDC92 |
| Cell migration | 8.0 | AP2M1, FSCN1, GNB1, TPM1, VIM, ACTB, TAGLN2 |
Figure 3Common cellular functions across the two data sets after comparison analysis. The bars represent the biological functions identified, named in the x-axis. The y-axis shows the −log of the P value calculated based on Fisher's exact test. The dotted line represents the threshold above which there are statistically significantly more genes in a biological function than expected by chance. The differences observed in the P-values for each function in between the two groups are due to differences in the number of proteins assigned and reference data set.